The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Abstract
Mutations in the p53 tumour-suppressor gene are the most frequently observed genetic lesions in human cancers. To investigate the role of the p53 gene in mammalian development and tumorigenesis, a null mutation was introduced into the gene by homologous recombination in murine embryonic stem cells. Mice homozygous for the null allele appear normal but are prone to the spontaneous development of a variety of neoplasms by 6 months of age. These observations indicate that a normal p53 gene is dispensable for embryonic development, that its absence predisposes the animal to neoplastic disease, and that an oncogenic mutant form of p53 is not obligatory for the genesis of many types of tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This enhanced muscle function, restoring the Dmd reading frame and enabling potential treatment for Duchenne muscular dystrophy.”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [13]
In the citing paper
“For instance, Tabebordbar [13] used adeno-associated viral vectors to deliver CRISPR/Cas9 into an mdx mouse model, deleting the mutated exon 23.”
From A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment (2024) · cites this paper as [13]
In the citing paper
“Tp53 - knockout mice are born at normal Mendelian ratios and lack apparent phenotypic alterations but are prone to develop spontaneous tumours at around 6 months of age 127,128 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [127]
In the citing paper
“Studies have revealed that after inactivation of the TP53 gene (encoding p53) in mice, cells lacking functional p53 cannot respond appropriately to external stimuli, resulting in a high probability of tumors [7].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [7]
In the citing paper
“Complete loss of Per2 function reduced the average life span of p53− /− mice from 6 months to 4 months”
From Disrupting Circadian Homeostasis of Sympathetic Signaling Promotes Tumor Development in Mice (2010) · cites this paper as [60]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p53 tumour suppressor gene
Levine, A. J., Momand, J. A., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,785
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P. M., Montgomery, C. A., Geske, R. S., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 1,997
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S. D., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,742
Mansour, S. L., Thomas, K. R., & Capecchi, M. R. (1988) · Nature · doi:10.1038/336348a0 · Cited by 1,683
Research works printed but not linked: 10
- Mowat, M., Cheng, A., Kicumca, N., Bernstein, A. & Benchimol, S. Nature 61, 2777–2781 (1985).
- Ben David, Y., Prideaux, V. R., Chow, V., Benchimol, S. & Bernstein, A. Oncogene 3, 179–185 (1988).
- Stürzbecher, H.-W. et al. Oncogene 5, 795–801 (1990).
- Shaulsky, G., Ben-Ze'ev, A. & Rotter, V. Oncogene 5, 1707–1711 (1990).
- Soussi, T., de Fromentel, C. C. & May, P. Oncogene 5, 945–952 (1990).
- Bradley, A. in Tetratocarcinomas and Embryonic Stem Cells: A Practical Approach (ed. Robertson, E. J.) 113–151 (IRL, Oxford, 1987).
- Stutman, O. Fed. Proc. Fed. Am. Soc. exp. Biol. 33, 2028–2032 (1974).
- Yandell, D. W. Proc. Am. Assoc. Cancer Res. 32, 459–460 (1991).
- Sepulveda, A. R. et al. Cancer Res. 49, 6108–6117 (1989).
- Slagle, B. L., Lanford, R. E., Medina, D. & Butel, J. S. Cancer Res. 42, 2155–2162 (1984).
Cited by
Sorted by citations
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Metadata
- Authors
- Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- Nature
- Published
- 1992-03
- Volume
- 356
- Issue
- 6366
- Pages
- 215-221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2126679757
- Cited by
- 4,649
- References
- 48
- Citations by year
- 2026: 16 · 2025: 48 · 2024: 51 · 2023: 74 · 2022: 76 · 2021: 80 · 2020: 86 · 2019: 92 · 2018: 84 · 2017: 96 · 2016: 119 · 2015: 89 · 2014: 121 · 2013: 146 · 2012: 157
- FWCI
- 82.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, tumor suppressor, spontaneous tumors, carcinogenesis, embryonic development, mouse model, neoplasms
- MeSH terms
- Alleles, Animals, Base Sequence, Blastocyst, DNA, Exons, Female, Genetic Vectors, Heterozygote, Homozygote, Male, Mice, Inbred CBA, Mice, Inbred C57BL, Mice, Transgenic, Molecular Sequence Data, Mutation, Neoplasms, Experimental, RNA, Messenger, Stem Cells, Blotting, Southern, Polymerase Chain Reaction, Genes, p53, Tumor Suppressor Protein p53, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
